Plasma hormones during cycle

Plasma hormones are the estrogen, progesterone, luteinizing hormone (LH), and follicle-stimulating hormone (FSH) measured in blood across the menstrual cycle. Their rise-and-fall patterns follow predictable phase-linked shifts across a typical ovulatory cycle ^[1]. For premenstrual dysphoric disorder (PMDD), research suggests symptom burden reflects sensitivity to those normal cyclical changes rather than necessarily abnormal routine hormone levels ^[2]—separate from phase names alone, which are covered in How do menstrual cycles work? For many people with PMDD, luteal-phase mood and body symptoms often build in step with those post-ovulation hormone curves.

Skim tip: For the PMDD takeaway first, jump to When luteal hormones meet PMDD or Normal curves, altered brain response.

Estrogen across the cycle

Estrogen (mainly estradiol) prepares the uterine lining and influences brain pathways tied to mood. At the start of the follicular phase, when menstrual bleeding begins, estrogen and progesterone are typically low and the uterine lining sheds if no pregnancy occurred ^[3]. The pituitary gland then increases follicle-stimulating hormone (FSH), which helps drive ovarian follicle development and a gradual estrogen rise ^[4].

Estrogen generally rises through the follicular phase, peaks near ovulation, and—after the empty follicle becomes the corpus luteum—continues alongside progesterone in the luteal phase before both fall sharply to trigger the next menses if fertilization does not occur ^[5]. Research reviews describe estrogen as a modulator of the serotonin system (a major mood-regulating brain chemical), with possible effects on serotonin synthesis, breakdown, and reuptake—though human PMDD-specific mechanism data remain limited ^[6]. For PMDD, reviews emphasize that the condition is not explained by a simple deficiency or excess of estrogen or progesterone on routine testing; sensitivity to normal cyclical shifts is the leading model ^[7].

Progesterone and neuroactive steroids

Progesterone prepares the uterus for possible pregnancy and is a central nervous system hormone as well. It predominates in the luteal phase, rising after ovulation while secretion patterns shift across early versus mid-to-late luteal portions of the cycle ^[8]. Progesterone is quickly converted to allopregnanolone, a neuroactive steroid that acts as a positive modulator of GABA-A receptors (brain receptors for the calming neurotransmitter GABA) ^[9]. This conversion occurs in two enzymatic steps ^[11].

Cycle-mapping studies show that allopregnanolone concentrations peak in the mid-luteal subphase, when enzymatic conversion from progesterone continues even as allopregnanolone levels plateau between early and mid-luteal portions ^[10]. This matters for PMDD because symptom timing tracks active ovarian hormone production after ovulation ^[16], not a single static lab value.

LH and FSH: pituitary signals

FSH and LH are gonadotropins (pituitary hormones that signal the ovaries) released by the pituitary gland; together they regulate follicle growth, ovulation, and corpus luteum function ^[12]. FSH stimulates ovarian follicle development early in the cycle, driving a gradual estrogen rise ^[13]. Estrogen peaks just before ovulation, when the dominant follicle releases a mature egg ^[14]. In the middle and late luteal phase, pulsatile LH release correlates with episodic progesterone secretion, and the frequency and amplitude of LH pulses gradually decrease—part of the wind-down toward the next cycle ^[15].

These pituitary hormones are usually drawn less often in routine PMDD care than estrogen and progesterone, but their ovulatory surge marks the transition from follicular to luteal physiology on which luteal hormone curves depend.

When luteal hormones meet PMDD

For many people with PMDD, the hardest window aligns with the luteal phase, when ovarian steroids fluctuate markedly. Reviews note pronounced cycling of estrogen and progesterone, with progesterone and its metabolite allopregnanolone closely linked to premenstrual symptom timing ^[16]. Symptoms require corpus luteum development and are absent during anovulatory cycles or when ovulation is suppressed medically ^[16]. Hormonal contraception, anovulatory cycles, polycystic ovary syndrome (PCOS), and perimenopause can suppress or alter ovulation—the hormone curves in this article describe a typical ovulatory cycle and may not match every person's experience.

Research summarized in recent research frameworks describes allopregnanolone as low in the follicular phase, rising after ovulation, and peaking in the mid-luteal phase ^[17]. Many prospectively confirmed PMDD symptom patterns emerge after ovulation, intensify across the luteal phase, and ease as menses begins ^[17].

That pattern is typical but not universal. Research summarized in recent frameworks also describes hypothesized, candidate timing forms—such as luteal-onset, perimenstrual-onset, and periovulatory-onset hormone-linked mood change—so symptom windows can differ between individuals ^[18]. Experimental add-back under ovarian suppression—in a research setting, cycle hormones are medically suppressed, then estradiol and/or progesterone are reintroduced—suggests estradiol dose and combined estradiol–progesterone exposure—not progesterone fluctuation alone—can re-provoke symptoms in people with PMDD ^[25]. Cyclical distress tied to hormones is a physiological pattern, not a character flaw.

Normal curves, altered brain response

A recurring finding across controlled studies and reviews is that people with PMDD generally show normal circulating estradiol and progesterone on routine testing ^[20]. The hypothalamic–pituitary–ovarian (HPO) axis—the brain–pituitary–ovary signaling system that coordinates the cycle—also typically functions normally on standard testing, yet clinical and imaging evidence points to a differential central nervous system response to physiologically normal hormone changes—including brain regions that react differently despite similar hormone exposure ^[19]. Some studies report phase-specific subgroup differences or early-luteal estrogen–progesterone interactions, but findings are mixed and do not replace the leading sensitivity model ^[24]. Peripheral luteal-phase allopregnanolone levels often do not differ from asymptomatic controls, supporting a model of altered brain sensitivity to normal neurosteroid fluctuations rather than a fixed high or low lab result ^[21].

Experimental work adds nuance: blocking the expected luteal rise in allopregnanolone reduced core PMDD symptoms in a small trial even when plasma progesterone stayed in the usual range, while the same manipulation did not affect asymptomatic controls—suggesting that changes in neurosteroid levels may be more relevant than absolute concentrations alone ^[22]. Narrative reviews similarly describe normal plasma allopregnanolone in many PMDD cohorts alongside altered GABAergic sensitivity to cyclical shifts ^[23]. For how brain circuits translate these signals into mood and behavior, see The Brain-Body Connection in PMDD.

Using hormone knowledge with PMDD

Understanding hormone curves can help interpret when symptoms tend to build and ease, support cycle-aligned symptom logging, and frame conversations with a qualified clinician—without treating a single blood draw as a PMDD diagnostic test.

• Track patterns, not single labs. Prospective daily ratings across cycles remain the standard for confirming PMDD timing; hormone charts in apps are learning tools, not substitutes for clinical assessment.
• Name the mechanism without self-blame. Normal cyclical hormones with an altered brain or neurosteroid response is a leading research model—not evidence that someone is "hormonally broken" on paper.
• Remember non-textbook cycles. Hormonal contraception, anovulatory cycles, PCOS, and perimenopause can suppress or alter ovulation—the curves here describe a typical ovulatory cycle and may not match yours.
• Bring timing notes to care visits. Logs that show luteal worsening and follicular relief can support treatment planning; persistent symptoms across the whole cycle may warrant evaluation for other conditions or premenstrual exacerbation (PME) rather than PMDD alone.

Many people find that pairing phase awareness from How do menstrual cycles work? with hormone-curve literacy makes symptom swings easier to anticipate. Treatment options are available, and accurate cycle-hormone context can support shared decisions with a healthcare provider.